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Sustained Suppression of Neointimal Proliferation by
Sirolimus-Eluting Stents
One-Year Angiographic and Intravascular Ultrasound Follow-Up
J. Eduardo Sousa, MD, PhD; Marco A. Costa, MD, PhD; Alexandre C. Abizaid, MD, PhD;
Benno J. Rensing, MD, PhD; Andrea S. Abizaid, MD; Luiz F. Tanajura, MD; Ken Kozuma, MD;
Glenn Van Langenhove, MD, PhD; Amanda G.M.R. Sousa, MD, PhD; Robert Falotico, PhD;
Judith Jaeger, BA; Jeffrey J. Popma, MD; Patrick W. Serruys, MD, PhD
Background—We have previously reported a virtual absence of neointimal hyperplasia 4 months after implantation of
sirolimus-eluting stents. The aim of the present investigation was to determine whether these results are sustained over
a period of 1 year.
Methods and Results—Forty-five patients with de novo coronary disease were successfully treated with the implantation
of a single sirolimus-eluting Bx VELOCITY stent in São Paulo, Brazil (n530, 15 fast release [group I, GI] and 15 slow
release [GII]) and Rotterdam, The Netherlands (15 slow release, GIII). Angiographic and volumetric intravascular
ultrasound (IVUS) follow-up was obtained at 4 and 12 months (GI and GII) and 6 months (GIII). In-stent minimal lumen
diameter and percent diameter stenosis remained essentially unchanged in all groups (at 12 months, GI and GII; at 6
months, GIII). Follow-up in-lesion minimal lumen diameter was 2.28 mm (GIII), 2.32 mm (GI), and 2.48 mm (GII). No
patient approached the $50% diameter stenosis at 1 year by angiography or IVUS assessment, and no edge restenosis
was observed. Neointimal hyperplasia, as detected by IVUS, was virtually absent at 6 months (265% obstruction
volume, GIII) and at 12 months (GI5265% and GII5263%).
Conclusions—This study demonstrates a sustained suppression of neointimal proliferation by sirolimus-eluting Bx
VELOCITY stents 1 year after implantation. (Circulation. 2001;104:2007-2011.)
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Despite major technological advances in the past decades,of which the coronary stent is one of the most important,
the percutaneous treatment of coronary artery disease is still
hampered by a 20% to 30% incidence of restenosis. The list
of candidate therapies and devices for prevention of resteno-
sis after angioplasty is long and ever expanding. However,
few if any have substantially improved the result of stenting
for the treatment of de novo lesions. Intracoronary radiation
has so far proven to be effective for the treatment of in-stent
restenosis but not for the treatment of de novo lesions.1 As a
result of their ability to deliver prolonged and sufficient
intramural drug concentrations to the target coronary seg-
ment, drug-eluting stents have emerged as a potential solution
for restenosis. Our group has recently reported an almost
complete absence of neointimal hyperplasia 4 months after
implantation of sirolimus-eluting Bx VELOCITY stents.2 The
local release of sirolimus (rapamycin, Rapamune), a natural
macrocyclic lactone with potent immunosuppressive action,3
resulted in elimination of restenosis in this first series of
patients. Comparable results have only been observed after
the implantation of high-activity b-emitting stents (9 mm3 of
neointimal hyperplasia at 6-month follow-up).4 However, a
worrying late progression of in-stent neointimal hyperplasia
was observed between 6 months and 1 year after implantation
of radioactive stents.5
See p 1996
The aim of the present investigation was to determine
whether sirolimus-eluting stents produce a sustained suppres-
sion of the neointimal proliferation over a period of 1 year or
merely delay the restenosis process.
Methods
Study Population
Forty-five patients with native coronary artery disease and angina
pectoris were successfully treated with the implantation of a single
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sirolimus-eluting Bx VELOCITY stent. Only lesions #18 mm in
length and vessels $3 and #3.5 mm in diameter were included.
Total occlusion, ostial or thrombus containing lesions, unprotected
left main disease with .50% stenosis, occurrence of myocardial
infarction within the preceding 72 hours, and left ventricular ejection
fraction ,30% were the major exclusion criteria. Thirty patients
were electively treated with two different formulations of sirolimus-
eluting stents (fast release [FR], n515, group I, and slow release
[SR], n515, group II) at the Institute Dante Pazzanese of Cardiolo-
gy, São Paulo, Brazil. A third cohort of patients (n515, group III)
was treated with SR sirolimus-eluting stents at the Thoraxcenter,
Erasmus University Rotterdam, The Netherlands.
Drug-Polymer Matrix and Elution Kinetics
Sirolimus was blended in a mixture of nonerodable polymers, and a
5-mm-thick layer of sirolimus-polymer matrix was applied onto the
surface of the Bx VELOCITY stent (Cordis), a laser-cut 316L
stainless-steel balloon-expandable stent.
The drug is almost completely eluted by 15 days after implantation
in the FR formulation. Another layer of drug-free polymer was
applied on top of the drug-polymer matrix to introduce a diffusion
barrier and prolong drug release to .28 days in the SR formulation.
All stents, regardless of the coating composition, were loaded with a
fixed amount of sirolimus per unit of metal surface area (140 mg
sirolimus/cm2).
In vivo experiments have shown that sirolimus levels in whole
blood peak at 1 hour (2.660.7 ng/mL, FR; 0.960.2 ng/mL, SR) after
implantation and fall below the lower limit of quantification by 72
hours (0.4 ng/mL) (Bruce D. Klugherz, unpublished data, 2000).
Taking into account that renal transplant patients maintain chronic
blood levels of rapamycin between 8 and 17 ng/mL, the peak blood
level after implantation of a sirolimus-eluting stent is absolutely
negligible.
Stent Procedure
Stents were implanted according to standard practice, after balloon
predilatation and followed by high-pressure (.12 atmospheres)
balloon after dilatation. All stents were 18 mm long and 3 to 3.5 mm
in diameter. Heparin was given to maintain the activated clotting
time .300 seconds. Patients received aspirin (325 mg/d, indefi-
nitely) started at least 12 hours before the procedure and a 300-mg
loading dose of clopidogrel immediately after stent implantation and
75 mg/d for 60 days. The protocol was approved by the Medical
Ethical Committees of both institutions, and written informed con-
sent was obtained from every patient.
Angiographic and IVUS Procedures
Patients in São Paulo (groups I and II) underwent intravascular
ultrasound (IVUS) and angiographic follow-up at 4 and 12 months.
In Rotterdam (group III), patients returned for repeat angiography
and IVUS assessment at 6 months, the classical restenosis time point.
Intracoronary nitrates were administered immediately before each
angiographic and IVUS acquisition. Postprocedure angiography was
performed in at least 2 orthogonal projections, which were repeated
at the follow-up studies. Quantitative angiographic analysis was
done by an independent core laboratory (Brigham and Women’s
Hospital, Boston, Mass).
The segments subject to three-dimensional (3D) IVUS reconstruc-
tion were examined with a 30-MHz single-element mechanical
transducer (ClearView, CVIS, Boston Scientific Corporation). A
constant pullback speed of 0.5 mm/s was used for IVUS image
acquisitions. A complete IVUS run was recorded on s-VHS tape for
offline 3D reconstruction. At 12 months, IVUS images were also
acquired using an ECG-triggered pullback device with a stepping
motor at 0.2 mm/step (EchoScan, Tomtec) to assure a precise
quantification of neointimal hyperplasia volume. This system ac-
quires images coinciding with the peak of the R wave, eliminating
the artifacts caused by the movement of the heart during the cardiac
cycle and ultimately improving the quality of image for 3D volu-
metric quantification. Volumetric IVUS analysis was carried out by
an independent core laboratory (Cardialysis BV, Rotterdam, The
Netherlands).6,7
Quantitative Measurements
Two coronary segments were subjected to quantitative angiography,
in-stent and in-lesion segments. The in-stent analysis encompassed
only the 18-mm-long segment covered by the stent. The in-lesion
segment was defined as the stent plus 5 mm proximal and 5 mm
distal to the edge or the nearest side branch. In-stent and in-lesion
restenosis was defined as $50% diameter stenosis (DS) at follow-up,
located within the stent and target lesion, respectively. Edge reste-
nosis was defined as $50% DS at follow-up, located at the proximal
or distal edge. Minimal lumen diameter (MLD) and percent DS were
calculated for each segment.
Quantitative IVUS analyses of the stent segment were performed
at all time points. Lumen and stent boundaries were detected using a
minimum-cost algorithm. Total stent and lumen volumes were
calculated as previously described. Intimal hyperplasia (IH) volume
was calculated as stent volume minus luminal volume. Feasibility,
reproducibility, and interobserver and intraobserver variability of
these measurements have been validated previously.8
Statistical Analysis
Continuous variables are expressed as mean6SD. Comparisons
between postintervention and follow-up measurements were per-
formed with a 2-tailed paired t test. Comparisons between groups
were performed using unpaired Student’s t test. A P value ,0.05 was
considered statistically significant.
Results
Baseline characteristics were similar between the 3 groups.
Overall, 29 patients were male, 32 had stable angina, and 13
were unstable. Mean age was 55.1 (group I), 57.9 (group II)
and 60 years (group III). Six patients had a history of diabetes
mellitus. Clopidogrel was discontinued at 60 days in all
patients.
At the Thoraxcenter, 1 of the 15 patients died on day 2 of
a cerebral hemorrhage. She had received abciximab during
the procedure and for 12 hours thereafter. Two additional
patients (group III) suffered a vessel occlusion during or
immediately after the procedure attributable to distal edge
dissection and were successfully treated with additional
stenting. Subsequent clinical follow-up was uneventful for
both patients, and no restenosis was detected at 6-month
angiographic follow-up. Finally, 1 asymptomatic patient from
Rotterdam refused repeat angiography; thus, 13 completed
6-month angiographic and IVUS follow-up. As reported
previously,2 all patients in groups I and II were discharged
without any clinical event. One asymptomatic patient (group
II) refused repeat angiography at 12 months.
A representative sequence of angiograms from a single
patient are shown in Figure 1. Preprocedure reference vessel
diameter (RD) was 2.8560.46 mm, and postprocedure MLD
was 2.4760.38-mm (in-lesion) and 2.960.27-mm (in-stent)
in the Rotterdam patients (group III). Four-month data from
groups I and II have been reported previously.2 One-year
in-stent MLD (group I, 2.7360.3 mm; group II,
2.8760.4 mm) and percent DS (group I, 8.966.1%; group II,
6.767%) remained essentially unchanged compared with
4-month follow-up. At 6 months (group III), in-stent MLD
was 2.6660.3 mm, and percent DS was 8.967.6% (P5NS
compared with postprocedure) Changes in in-lesion MLD
and percent DS are shown in Figure 2. At 12 months,
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in-lesion angiographic lumen dimension showed a small
decrease compared with postprocedure in both groups (Figure
2, P,0.01). Between 4 months and 12 months, a very small
decrease, albeit statically significant (P50.004), in in-lesion
MLD was observed in group I. No patient approached the
$50% DS at 1-year by angiography or IVUS assessment, and
no edge restenosis was observed.
At 6-month follow-up, lumen volume was 156.7663.6
mm3 (versus 156.5664.1 mm3 at postprocedure, P5NS) and
intimal hyperplasia volume was 5.7617.7 mm3 (group III).
Thus, the percent obstruction volume was 264.98%, similar
to the results reported at 4 months in the patients from São
Paulo.2
One-year volumetric IVUS data (Figure 3) from the São
Paulo patients were actually better than those reported previ-
ously at 4-month follow-up.2 Only 2 patients had .10% IH
after 12 months (Figure 3). Differences in the method of
volumetric quantification probably explain these findings. As
a result of the virtual absence of neointimal hyperplasia, the
automated contour detection algorithm that was used for the
original analysis superimposed the contours of the stent and
lumen boundaries in the majority of the cases. Thus, the core
laboratory analyst used a “copy and shrink” tool of the
quantitative analysis software to dissociate the two contours.
This action led to an overestimation of the amount of IH. At
12-month follow-up analysis, the lumen and stent contours
were not dissociated artificially, unless IH was clearly visu-
alized. To compare 4-month and 12-month IVUS data, the
core laboratory reanalyzed the 4-month IVUS images using
the same methodology used at 12 months (Table).
In one patient (group I), 12-month IVUS assessment
showed an unstable plaque proximal to the stent. Lesion
vulnerability was characterized by positive vessel remodeling
and a large lipid pool delimited by a thin fibrous cap (Figure
4). This preexisting plaque increased progressively from the
time of the initial procedure, producing a linear deterioration
in lumen dimensions (MLD was 2.85 mm postprocedure,
2.51 mm at 4 months, and 2.02 mm at 12 months). No sign of
thrombus was detected by angiography or IVUS. At 12
months, the patient was asymptomatic and had a negative
stress test. However, at 14-month follow-up, he returned with
a non–Q-wave myocardial infarction. Angiography showed
Figure 1. Angiography shows a lesion in the mid portion of the
left circumflex marginal branch (white arrow), which was treated
with the implantation of a sirolimus-coated BX-velocity stent
(top right). Lumen dimensions remained unchanged at 4- and
12- month follow-up (bottom).
Figure 2. In-lesion percent diameter ste-
nosis (%DS) and MLD over a period of 1
year. Angiographic follow-up was per-
formed at 4 and 12 months in group I
(GI) and GII and at 6 months in GIII.
Figure 3. Cumulative distribution curves of percent obstruction
volumes in group I (left) and group II (right) at 12-month follow-
up. Longitudinal IVUS reconstruction illustrates the virtual
absence of in-stent intimal hyperplasia at 12 months (bottom).
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the target vessel occluded proximal to the stent, and repeat
angioplasty was performed.
The remaining 29 patients of the first 2 cohorts (groups I
and II) have now completed 15-month clinical follow-up
uneventfully. Similarly, the 14 Rotterdam patients were
asymptomatic, with no additional adverse events up to 9
months after the index procedure.
Discussion
The present study demonstrates a potent, long-lasting inhib-
itory effect on neointimal proliferation exerted by the local
release of sirolimus via a stent platform. Regardless of the
coating formulation (SR or FR) or population treated (São
Paulo or Rotterdam), neointimal hyperplasia, as detected by
both angiography and volumetric IVUS quantification, was
minimal at all time points (4, 6, or 12 months).
The lack of restenosis observed in this first series of
patients treated with sirolimus-eluting Bx VELOCITY stents
is probably a consequence of the scaffolding properties of the
stent as well as the potent cytostatic effect of sirolimus.9,10
Like cyclosporin A and tacrolimus (FK506), sirolimus binds
to specific cytosolic proteins. However, the mechanism of
action of sirolimus is distinct from other immunosuppressive
agents that act solely by inhibiting DNA synthesis. The
sirolimus:FKBP complex binds to a specific cell-cycle regu-
latory protein, the mTOR (mammalian target of rapamycin),
and inhibits its activation.11 The inhibition of mTOR induces
cell-cycle arrest in late G1 phase.12–14 The upregulation of
FK506-binding protein 12 (FKBP12) observed in human
neointimal smooth muscle cells additionally supports the
potential antirestenotic effect of sirolimus.15 Preclinical data
have demonstrated the efficacy of both systemic13,16 and local
administration (via drug-eluting stent) (Andrew J. Carter,
unpublished data, 2000) of sirolimus in reducing neointimal
hyperplasia in different models of restenosis.
A concern about potential late complications, such as late
thrombosis, associated with new therapies is a legacy from
our previous experience with intracoronary radiation thera-
py.17 In our series, one patient (out of 44) experienced a
thrombotic event involving the target coronary artery 14
months after the procedure. It is important to note that IVUS
showed an unstable plaque located proximal to the stent that
grew progressively in size over the period of observation. The
relationship between unstable plaque, as characterized by
IVUS, and coronary thrombosis has been reported previously
and may explain this unexpected event.18,19 Experimental
investigations have shown a similar degree of re-endotheli-
alization between bare and sirolimus-coated stents occurring
as early as 30 days after implantation (Andrew J Carter,
unpublished data, 2001), ie, sirolimus does not seem to delay
endothelialization. Nevertheless, one cannot completely rule
out the possibility of late-stent thrombosis as a cause of vessel
occlusion in this case. The occurrence of this somewhat
anecdotal event should be interpreted with caution. Data from
large randomized multicenter trials, already underway, will
be necessary to definitively address this important question.
After our previous study showing a surprising near-
absence of IH 4 months after implantation of sirolimus-
eluting stents,2 the logical question was whether this effect
would be permanent or whether it merely represented a delay
in the proliferative response. The basis for these concerns is
the unexpected late-luminal deterioration observed with
catheter-based radiation systems and radioactive stents,1,5
although the mechanisms of action of sirolimus-eluting stents
differ considerably from intracoronary brachytherapy. In the
present study, angiographic lumen dimensions and IVUS-
detected IH volume assessed both at 6-month follow-up (in
group III) and at 12 months (groups I and II) was not
substantially different from what was observed at 4 months
(Table). Thus, at 12-month follow-up, there is no evidence of
significant late catch up, and the 12-month IH volume
observed in the present study is less than one third of that
reported with any previously tested antirestenosis therapy.6,7
If the findings of the present investigation are confirmed by
large, randomized, placebo-controlled trials, this technology
is likely to have a major impact on the treatment of coronary
artery disease in the near future.
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